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Hepatocyte nuclear factor 4 alpha (HNF4α) is a transcription factor that plays a critical role in hepatocyte function, 
and HNF4α-based reprogramming corrects terminal liver failure in rats with chronic liver disease. In the livers of 
patients with advanced cirrhosis, HNF4α RNA expression levels decrease as hepatic function deteriorates, and protein 
expression is found in the cytoplasm. These findings could explain impaired hepatic function in patients with degenera-
tive liver disease. In this study, we analyzed HNF4α localization and the pathways involved in post-translational modi-
fication of HNF4α in human hepatocytes from patients with decompensated liver function. RNA-sequencing analysis 
revealed that AKT-related pathways, specifically phospho-AKT, is down-regulated in cirrhotic hepatocytes from pa-
tients with terminal failure, in whom nuclear levels of HNF4α were significantly reduced, and cytoplasmic expression 
of HNF4α was increased. cMET was also significantly reduced in failing hepatocytes. Moreover, metabolic profiling 
showed a glycolytic phenotype in failing human hepatocytes. The contribution of cMET and phospho-AKT to nu-
clear localization of HNF4α was confirmed using Spearman’s rank correlation test and pathway analysis, and further 
correlated with hepatic dysfunction by principal component analysis. HNF4α acetylation, a posttranslational modifica-
tion important for nuclear retention, was also significantly reduced in failing human hepatocytes when compared with 
normal controls. Conclusion: These results suggest that the alterations in the cMET-AKT pathway directly correlate 
with HNF4α localization and level of hepatocyte dysfunction. This study suggests that manipulation of HNF4α and 
pathways involved in HNF4α posttranslational modification may restore hepatocyte function in patients with terminal 
liver failure. (Hepatology Communications 2020;0:1-17).
Terminal liver failure resulting from degener-ative disease represented the twelfth leading cause of death in 2015.(1) In the United States, 
the number of registered deaths coupled with chronic 
liver disease and cirrhosis in that year was 40,326.(2) 
The most affected age range was 45-64 year-olds. 
and it was the fourth leading cause of death in that 
age group.(2) The only definitive therapy for end-
stage liver failure is orthotopic liver transplantation, 
which—given the number of patients in need of 
liver transplants and the insufficient number of 
donor organs—makes it nearly untreatable for many 
patients.(3)
There are numerous causes of chronic liver dis-
ease, including chronic infection by hepatitis viruses, 
alcohol-mediated cirrhosis, and nonalcoholic steato-
hepatitis (NASH),(4) and each can produce hepato-
cellular failure.(5,6) The mechanisms responsible for 
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deterioration of hepatocyte function and ultimately 
hepatic failure in man are poorly understood. Chronic 
hepatic damage produces oxidative stress(7) and endo-
plasmic stress,(8) which can induce cell death(8-10) and 
reduce the proliferative capacity of the hepatocytes.(11)
In previously published studies, we found that liv-
er-enriched transcription factors are stably down-reg-
ulated in hepatocytes from rats with end-stage 
cirrhosis,(12) and that forced re-expression of one of 
them, hepatocyte nuclear factor 4 alpha (HNF4α), 
reprograms dysfunctional hepatocytes to regain func-
tion, both in culture and in vivo.(12) We have also 
shown in a large cohort of patients with advanced 
liver disease that the level of HNF4α messenger RNA 
(mRNA) expression in the diseased liver correlated 
with extent of hepatic dysfunction (Childs-Pugh clas-
sification) and that HNF4α expression was not local-
ized in the nucleus, as was the case in our rat studies.(5)
HNF4α is a transcription factor that plays a criti-
cal role in liver organogenesis and hepatocyte function 
in the mature liver,(12,13) and its expression and func-
tion are regulated at multiple levels.(14-23) It must be 
expressed in the nucleus to function properly; there-
fore, we analyzed the signaling pathways involved 
in nuclear localization of HNF4α in hepatocytes 
isolated from explanted human livers with decom-
pensated function. In this analysis involving a sig-
nificantly smaller cohort of patients, we were able to 
demonstrate that decompensated livers have signifi-
cantly lower expression of nuclear HNF4α and higher 
expression of cytoplasmic HNF4α when compared 
with normal controls and correlated with low levels 
of cMET and phosphorylated AKT (protein kinase 
B). Moreover, we found that hepatic dysfunction 
correlated directly with a reduction in the nuclear 
acetylation of HNF4α. Thus, posttranslational modi-
fications are important for HNF4α localization in the 
nucleus. Transcriptional activation may be responsible 
for deterioration of hepatocyte functional in human 
cirrhotic livers with terminal failure.
Materials and Methods
Human samples anD 
HepatoCyte isolation
De-identified normal human liver tissue and/or 
cells were obtained through the Liver Tissue Cell 
Distribution System (Pittsburgh, PA) after obtaining 
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written, informed consent by a protocol approved 
by the Human Research Review Committee of 
the University of Pittsburgh, which was funded 
by National Institutes of Health Contract No. 
HSN276201200017C. Adult human liver tissue and/or 
cells were also obtained from the Fox Laboratory at the 
Children’s Hospital of UPMC, after obtaining written 
informed consent by an expedited protocol approved 
by the Human Research Review Committee and the 
Institutional Review Board (IRB#: PRO12090466) of 
the University of Pittsburgh (Table  1). Hepatocytes 
were isolated using a three-step collagenase digestion 
technique as previously described.(24) Cell viability 
was assessed after isolation as previously described 
using trypan blue exclusion, and only cell preparations 
with viability > 80% were used for the analysis.
IN SILICO HnF4α 
posttRanslational 
moDiFiCations analysis
To identify the posttranslational modifications 
(PTMs) that modulate HNF4α cellular localization, an 
in silico analysis was performed through computational 
searches in databases and publications (Supporting 
Fig. S1A). The process was divided into three phases: 
identification, screening, and selection. Initially, 51 
PTMs were identified. Next, during the screening phase, 
23 PTMs were selected by the application of two elim-
ination criteria (Supporting Fig. S1B). Two phosphory-
lation and one acetylation modifications were identified 
in the selection phase as the most plausible PTMs 
related to HNF4α localization able to be evaluated.
staBle isotope analysis using 
gas CHRomatogRapHy–mass 
speCtRometRy
One million human hepatocytes were cultured with 
Dulbecco’s modified Eagle’s medium F12 in the pres-
ence of 13-C6-labeled glucose and glutamine isotope 
tracers for 96 hours (Thermo Fisher Scientific, San 
Jose, CA). The medium was removed and cells were 
washed with ice-cold phosphate-buffered saline solu-
tion. Next, cells were quenched with 400 μL methanol 
and 400 μL water containing 1 μL norvaline, scraped, 
washed with 800 μL ice-cold chloroform, vortexed at 
4°C for 30 minutes, and centrifuged at 7,300  rpm for 
10 minutes at 4°C. The upper aqueous phase was col-
lected for metabolite analysis. Metabolite extracts were 
centrifuged at 14,000g for 10 minutes to separate the 
polar phase, protein interphase, and chloroform phase. 
The water/methanol phase–containing polar metab-
olites were transferred to fresh microcentrifuge tubes 
and dried in a SpeedVac and stored at −80°C until gas 
chromatography–mass spectrometry (GC-MS) anal-
ysis. Then, 30 µL of methoxyamine hydrochloride 
(Thermo Scientific) was added to dried samples and 
incubated at 30°C for 2  hours with intermittent vor-
texing. A total of 45 µL of MBTSTFA  +  1% tert- 
butyldimethylchlorosilane was added to the samples and 
incubated at 55°C for 1 hour. Derivatized samples were 
transferred to gas chromatography (GC) vials with glass 
inserts and added to the GC-MS autosampler. GC-MS 
analysis was performed using an Agilent 7890 GC 
(Santa Clara, CA) equipped with a 30-m HP-5MSUI 
capillary column connected to an Agilent 5977B mass 
taBle 1. CliniCal paRameteRs oF tHe patients in tHis stuDy
Etiology/Code, n Age (years) Sex (M, F) Total Bilirubin (mg/dL) Albumin (9/dL) MELD Child-Pugh
Healthy liver, 4 64 ± 13 2, 2 — — — —
NASH, 5 60 ± 10 2, 3 1.76 ± 0.6 2.9 ± 0.1 12.4 ± 6.1 9.4 ± 0.9
NASH 1 71 0, 1 1.7 3.0 8 9 (B)
NASH 2 68 0, 1 1.7 2.9 8 9 (B)
NASH 3 53 1, 0 1.1 2.8 8 9 (B)
NASH 4 59 1, 0 1.6 2.8 21 11 (C)
NASH 5 48 0, 1 2.7 3.0 17 9 (B)
Alcohol, 2 55 ± 5 3, 0 2.03 ± 1.0 2.53 ± 0.6 14.0 ± 2.6 10.0 ± 1.0
Alcohol 1 52 1, 0 1.5 1.9 16 11 (C)
Alcohol 2 61 1, 0 1.4 3.2 11 9 (B)
Abbreviations: F, female; M, male; MELD, Model for End-Stage Liver Disease.
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spectrometer. For polar metabolites, the following heat-
ing cycle was used for the GC oven: 100°C for 3 minutes, 
followed by a ramp of 5°C/minute to 300°C and held 
at 300°C for a total run time of 48 minutes. Data were 
acquired in scan mode. The relative abundance of 
metabolites was calculated from the integrated signal of 
all potentially labeled ions for each metabolite fragment. 
Mass isotopologue distributions were corrected for nat-
ural abundance using IsoCorrectoR prior to analysis 
with the model. Metabolite levels were normalized to 
internal standard Norvaline’s signal. Fractional enrich-
ment calculation represents the fractional contribution 
of 13C from a substrate to intermediate metabolite. It 
is calculated as follows:
where NC is the number of carbons that can be 




Paraffin-embedded liver tissue was deparaffinized 
with xylenes and dehydrated with ethanol. Antigen 
unmasking was performed by boiling in citrate buffer 
at pH  =  6.0. The slides were then incubated in 3% 
hydrogen peroxide, blocked with normal animal serum, 
and subsequently left incubating overnight at 4°C with 
primary antibodies. The primary antibodies used are 
listed in Supporting Table  S1. Tissue sections were 
then incubated with biotinylated secondary antibody 
corresponding to the animal species of the primary 
antibody (BA-1000; Vector Laboratories, Burlingame, 
CA) and exposed to 3,3′-diaminobenzidine (SK-4105; 
Vector Laboratories) to visualize the peroxidase activity. 
Counterstaining was performed with Richard-Allan 
Scientific Signature Series Hematoxylin (Thermo 
Fisher Scientific). For quantification, immunoreactiv-
ities of nuclear and cytoplasmic HNF4α were inde-
pendently graded by 2 liver pathologists, with 1,000 
hepatocytes in three high-power fields being counted 
per sample. Normal livers (n  =  4), Child-Pugh B 
(n = 5), and Child-Pugh C (n = 2) were included for 
these analyses. The Child-Pugh B and C livers were 
grouped as cirrhotic human liver, and the results are 
expressed as percentage over the total number of cells 
counted.
pRotein eXtRaCtion anD 
WesteRn Blotting
To perform protein-expression analysis, the isolated 
hepatocytes were divided in two fractions: One frac-
tion was used for total protein extraction, according to 
standard procedures previously described,(25) and the 
other fraction was used for nuclear protein isolation. 
For nuclear protein isolation, between 1  ×  107 and 
5  ×  107 isolated hepatocytes per patient were washed 
and harvested in 40 mmol/L Tris (pH 7.6), 14 mmol/L 
NaCl, and 1 mmol/L ethylene diamine tetraacetic acid 
(EDTA), then centrifuged (5  minutes, 100g). Cell 
pellets were suspended in 2  mL of hypotonic buffer 
(10  mmol/L 4-[2-hydroxyethyl]-1-piperazine ethane-
sulfonic acid [HEPES; pH 7.9], 10 mmol/L NaH2PO4, 
1.5 mmol/L MgCl2, 1 mmol/L dithiothreitol [DTT], 
0.5 mmol/L spermidine, and 1 mol/L NaF with pro-
tease and phosphatase inhibitor cocktails [Sigma, St. 
Louis, MO]). Following 10 minutes of incubation on 
ice, samples were homogenized in a Dounce homoge-
nizer and then centrifuged (5 minutes, 800g). Cell lysis 
was monitored with trypan blue stain. Supernatants 
were saved as cytoplasmic extracts. The nuclei pellets 
were washed two additional times in the same buffer.
Nuclear proteins were extracted in 50-100 μL of 
hypertonic buffer (30  mmol/L HEPES [pH 7.9], 
25% glycerol, 450 mmol/L NaCl, 12 mmol/L MgCl2, 
1 mmol/L DTT, and 0.1 mmol/L EDTA with prote-
ase and phosphatase inhibitor cocktails [Sigma]) for 
45 minutes at 4°C with continuous agitation. Extracts 
were centrifuged at 30,000g, and the supernatants 
were collected and dialyzed for 2  hours against the 
same solution but containing 150  mmol/L NaCl. 
Protein concentration was determined by the bicin-
choninic acid assay (Sigma).
Western blot analysis was performed according to 
standard procedures.(26) The intensity of each protein 
band was quantitated using National Institutes of 
Health Image J software.(27) The primary antibodies 
and dilutions are listed in Supporting Table S1.
Rna-seQuenCing anD analysis
Whole-genome strand-specific RNA-sequencing 
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levels from human isolated primary hepatocytes 
(Supporting Table  S2). RNA-Seq libraries were 
prepared as described previously(28) and in the 
literature.(29) RNA was extracted from human 
hepatocytes using TRIzol, followed by column 
purification (Zymo RNA clean and concentrator 
column) according to the manufacturers’ instruc-
tions. Total RNA was depleted of ribosomal RNA 
using pooled antisense oligo hybridization and 
depletion through RNaseH digestion as previously 
described.(30,31) Following purification over a Zymo 
RNA clean and concentrator column, first-strand 
complementary DNA (cDNA) was synthesized. 
Subsequently, second -strand cDNA was synthe-
sized, purified, and fragmented. RNA-seq libraries 
were prepared using Illumina technology. Briefly, 
end repair, A-tailing, and barcoded adapter ligation 
were followed by polymerase chain reaction amplifi-
cation and size selection. The integrity of the librar-
ies was confirmed by quBit quantification, fragment 
analyzer size distribution assessment, and Sanger 
sequencing of about 10 fragments from each library. 
Libraries were sequenced using paired-end Illumina 
sequencing.
Paired-end reads were aligned to hg38 using 
QIAGEN’s CLC Genomics workbench and assessed 
as transcript per million. To sort the data, K-means 
clustering was performed using Cluster 3.0,(32) and 
heatmaps were generated using Java Treeview.(33) The 
default settings for mismatch,(2) insertion cost,(3) were 
deletion cost(3) were used. Ingenuity pathway analy-
sis (IPA) was used to identify differentially expressed 
genes, predict downstream effects, and identify targets 
(QIAGEN Bioinformatics; www.qiagen.com/ingen 
uity). Regulatory effects analysis within IPA was used 
to identify the relationships between upstream regula-
tors and biological functions. The default setting was 
used in the analysis (i.e., the upstream regulators were 
limited to genes, RNA, and proteins). The RNA-
seq data are available at Gene Expression Omnibus 
(accession number GSE13 4422).
aKt inHiBition in noRmal 
Human HepatoCytes
Normal human hepatocytes (1 million cells/well) 
were cultured on collagen-coated wells. Cells were 
culture for 6 hours in the absence of growth factors or 
serum. Cells then were treated with 5 µM of MK-2206 
(Cayman Chemical, Ann Arbor, Michigan), an AKT 
inhibitor, for 24  hours. Total, cytoplasmatic, and 
nuclear protein were extracted for western blotting as 
described previously.
statistiCal analysis
Data were expressed as mean  ±  SD. Results from 
western blot analysis for two statistical groups were 
evaluated by Mann-Whitney nonparametric test and 
for three statistical groups by Kruskal–Wallis non-
parametric test. The comparisons among groups were 
performed by Dunn multiple comparisons test. The 
association among the analyzed proteins was eval-
uated using the Spearman’s rank correlation test. 
Linear regression was used to describe the relation 
between protein expression and clinical status, mea-
sured as Child-Pugh score. Statistics were performed 
using Prism 4.0 (GraphPad Software Inc., San Diego, 
CA). Differences were considered significant when 
P < 0.05.
To identify the direct dependence between the 
proteins analyzed by western blot, the path analysis 
(structural equation model) was used. The objective of 
the path analysis model is to explain a possible causal 
association between the observed correlations among 
a dependent variable and multiple independent vari-
ables. The path model was tested and modified by 
adding and removing a path based on the research 
framework and the results of regression weights and 
model fit. The results are plotted as diagrams that 
show the direct and indirect effects of the variables 
on the study system. The degree of correlation and 
the linear relation between variables is determined by 
a P value  less than  0.05 and an arbitrary coefficient 
that shows the level of importance (larger number 
represent a larger relation). The path analysis was per-
formed using InfoStat version 2013 (Grupo InfoStat, 
FCA, Universidad Nacional de Córdoba, Córdoba, 
Argentina). Unsupervised multivariate principal com-
ponent analysis (PCA) was applied to western blot 
data to reveal the group of proteins that distinguish 
among the sample’s clinical status. Scatter plots of the 
principal components that explain most of the vari-
ance were drawn. The statistical software JMP ver-
sion 14 (SAS Institute, Cary, NC) was used for PCA 
analysis.
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Results
HnF4α nuCleaR loCaliZation 
is DeCReaseD in Human 
liVeRs WitH enD-stage liVeR 
FailuRe, WHile CytoplasmiC 
loCaliZation is inCReaseD
HNF4α functions as a transcription factor, and nu-
clear localization is required for activity.(13-20,22,23,25,34,35)  
Therefore, we performed immunohistochemistry 
and western blot on hepatocytes from diseased liver 
specimens to determine the location of HNF4α and 
to correlate expression with hepatic decompensation. 
About 78% of hepatocytes from livers with terminal 
liver failure showed only cytoplasm expression or cyto-
plasm and weak nuclear expression of HNF4α, whereas 
normal human livers displayed 75% of hepatocytes with 
strong nuclear localization of HNF4α (Fig.  1A,B). 
Total HNF4α protein expression from isolated hepato-
cytes, as assessed by western blot, did not show any sta-
tistical difference between end-stage livers and normal 
controls (P = 0.166; Fig. 1C and Supporting Fig. S1A). 
This result was not surprising, as the ability to discern a 
Fig. 1. HNF4α location in hepatocytes from normal and cirrhotic livers. (A) Immunohistochemical staining micrographs of HNF4α 
show cytoplasmic and nuclear decrease of HNF4α expression in NASH and alcohol-mediated Laennec’s cirrhotic decompensated 
human livers (n = 6) compared with healthy human livers (n = 3). (B) Quantification of nuclear or/and cytoplasmic HNF4α expression 
in immunohistochemical staining micrographs. (C) Representative photographs of HNF4α immunofluorescence of isolated human 
hepatocytes from NASH decompensated liver and normal human hepatocytes. Western blot analysis and quantification of HNF4α 
normalized to B-actin in hepatocytes isolated from functionally decompensated livers (NASH and alcohol-mediated Laennec’s cirrhosis) 
(n = 6) and hepatocytes isolated from healthy liver controls (n = 2) (P = 0.166). (D) Western blot analysis and quantification of cytoplasm 
HNF4α: healthy human hepatocytes versus decompensated human hepatocytes, normalized to B-actin (P = 0.023). (E) Western blot 
analysis and quantification of nuclear HNF4α: healthy human hepatocytes versus decompensated human hepatocytes, normalized to 
nuclear marker histone deacetylase 1 (HDAC1; P = 0.023). Bar graphs from (C)-(E) are plotted as the mean ± SD; P < 0.05. Abbreviation: 
DAPI, 4′,6-diamidino-2-phenylindole.
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difference in HNF4α expression in livers from patients 
with degenerative disease and controls based on degree 
of functional decompensation required the study of 
a large cohort of patients.(5) However, in this study, a 
statistically significant difference was observed based on 
HNF4α location. HNF4α was detected at high levels 
in the cytoplasm (P  =  0.023; Fig.  1D and Supporting 
Fig. S1B) and at low levels in the nucleus (P = 0.023; 
Fig. 1E and Supporting Fig. S1C) of hepatocytes iso-
lated from functionally decompensated livers when com-
pared with hepatocytes isolated from normal controls.
Because the function and stability of HNF4α are 
regulated by a number of posttranslational modifi-
ers,(14-23) and because its nuclear localization is critical 
to its activity, we performed an in silico analysis to eval-
uate which modifiers regulate HNF4α localization. 
We found that adenosine monophosphate–activated 
protein kinase α (AMPKα) activation controls 
HNF4α transcription.(16) In addition, acetylation of 
HNF4α, which may be mediated by the AKT path-
way, stabilizes the molecule, favoring its retention in 
the nucleus (Supporting Fig. S2A,B).(19)
HnF4α is tHe maJoR RegulatoR 
oF Human HepatoCyte 
FunCtion in aDVanCeD liVeR 
Disease
Next, we examined gene-expression differences 
between human hepatocytes from normal controls 
(n = 4) and those recovered from patients with cirrho-
sis and terminal liver failure (n = 4) (Child-Pugh C), 
limiting our study to patients with NASH and alcohol- 
mediated Laennec’s cirrhosis. Hierarchical clustering 
of RNA-seq data revealed three major dynamic pat-
terns associated with cirrhosis and liver dysfunction 
(Fig. 2A), as shown in the heatmap of a k-means clus-
tering (log2 fold change over controls; k = 3). Cluster 1 
(3,478 genes) and cluster 3 (1,669 genes) represented 
genes that were moderately to highly up-regulated in 
hepatocytes from patients with terminal liver failure 
relative to control human hepatocytes. Most genes in 
these clusters were related to autophagy and apoptotic 
signaling (Fig. 2A).
Cluster 2, however, consisted of 1,669 genes that 
were significantly down-regulated in end-stage 
hepatocytes, and included genes encoding the serine- 
threonine protein kinase (AKT1), cytochrome P450s 
(cytochrome P450 [CYP]c8, CYP2c9, CYP2e1, and 
CYP3A4), and hepatocyte nuclear factors (HNF4α and 
forkhead box a1 [FOXa1]). The top pathways repre-
sented in this cluster included farnesoid X receptor/ 
retinoid X receptor (RXR) and liver X receptor/
RXR activation, mitochondrial dysfunction, oxida-
tive phosphorylation, and inhibition of RXR func-
tion (Supporting Figures S3 and S4). A core pathway 
analysis using IPA on these down-regulated genes 
showed that HNF4α was a central upstream regulator 
(Fig. 2B), and the heatmap confirmed many similari-
ties in the gene-expression profile of hepatocytes from 
patients with NASH and alcohol-mediated Laennec’s 
cirrhosis (Fig.  2C). These results were nearly identi-
cal to the gene-expression profile that we previously 
described of rat hepatocytes that were recovered from 
cirrhotic livers with terminal failure.(36)
Human HepatoCytes FRom 
liVeRs WitH enD-stage liVeR 
FailuRe Rely on pyRuVate 
DeHyDRogenase anD 
ReDuCtiVe CaRBoXylation 
oF glutamine to maintain 
tRiCHloRoaCetiC aCiD CyCle 
aCtiVity
Previously, we postulated that rat hepatocytes 
undergo an adaptive metabolic shift from gener-
ating energy predominantly from oxidative phos-
phorylation to glycolysis, allowing maintenance of 
energy homeostasis during stages of liver injury.(36,37) 
Because HNF4α is a positive transcriptional regula-
tor for controlling energy metabolism,(38-40) we inves-
tigate functionally the metabolite sources of energy 
in the trichloroacetic acid (TCA) cycle in human 
hepatocytes from livers with end-stage liver fail-
ure by performing [U-13C6]glucose and glutamine 
tracing analysis. Central carbon metabolism of cir-
rhotic hepatocytes relies on distinct carbon sources 
compared with healthy hepatocytes. Glucose con-
tribution to glycolytic intermediates and alanine are 
markedly increased in cirrhotic hepatocytes compared 
with normal hepatocytes (Fig. 3, P < 10−4, two-tailed 
t test). Although glucose contribution to other amino 
acids and TCA cycle intermediates are similar across 
the two groups, cirrhotic failing hepatocytes rely on 
increased pyruvate dehydrogenase flux as an anaple-
rotic source for the TCA cycle, due to a commensu-
rate decrease in pyruvate carboxylase flux (Supporting 
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Fig. S5). On the other hand, glutamine contribution 
to glutamate and α-ketoglutarate decreased in cir-
rhotic hepatocytes compared with normal human 
hepatocytes (Fig. 3, P < 0.01, two-tailed t test), but the 
13-carbon enrichment of downstream TCA metabo-
lites is similar across the two groups. This indicates 
an effective increase in the net glutamine contribution 
to downstream TCA metabolites. Importantly, the 
reductive carboxylation of glutamine is increased in 
cirrhotic hepatocytes compared with normal human 
hepatocytes, (Supporting Fig. S5B). Interestingly, the 
malic enzyme flux is decreased in cirrhotic hepato-
cytes compared with healthy controls (Supporting 
Fig.  S5C). Together, this indicates the increased use 
of glutamine in cirrhotic hepatocytes in the TCA 
cycle, which indicates dysfunction of oxidative TCA. 
These results are in accordance to the metabolic pro-
filing that we previously described of rat hepatocytes 
that were recovered from cirrhotic livers with terminal 
failure.(36,37)
Fig. 2. RNA-seq analysis from human hepatocytes recovered from healthy liver specimens, NASH, and alcohol-mediated Laennec’s 
cirrhotic explanted livers. (A) K-means clustering of log2 fold change differentially expressed genes from hepatocytes isolated from livers 
with NASH (n = 2) or alcohol-mediated Laennec’s cirrhosis (n = 2) and terminal liver failure relative to healthy hepatocytes (n = 3) 
demonstrated significant gene-expression changes. (B) The RNA-seq results suggest that the cirrhotic hepatocytes are expressing genes 
that simultaneously drive both proliferation and apoptosis, with an effected metabolism (clusters 1, 2, and 3), under the control of upstream 
regulators (cluster 2). This regulatory process involves the actions of HNF4α and AKT1. (C) Heatmaps for the top molecular and 
cellular functions altered in NASH and alcohol-mediated Laennec’s cirrhotic hepatocytes included down-regulation of functions related 
to small molecules biochemistry, lipid metabolism and molecular transports, and up-regulation of molecular functions related to cancer 
and organismal injury and abnormalities.
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cmet anD aKt 
pHospHoRylation CoRRelate 
WitH HnF4α nuCleaR 
loCaliZation in Human 
HepatoCytes FRom patients 
WitH enD-stage liVeR FailuRe
Because epidermal growth factor receptor 
(EGFR) and cMET have been shown to regulate 
the AMPK and AKT pathways(41-43) that were 
identified in our in silico and RNA-seq analysis as 
important modulators of HNF4α, we performed 
antibody-based assays for these molecules in our 
liver specimens. cMET expression in decompen-
sated liver specimens (Fig. 4) was markedly reduced 
when measured by both immunohistochemistry and 
western blot (P  =  0.023; Fig.  5A,B) when com-
pared with isolated control human hepatocytes. 
Fig. 3. Mapping of carbon atom transitions using uniformly labeled 13-C6-glucose and glutamine. (A) Estimation of carbon 
contribution from various substrates in human cirrhotic (n = 3) and normal hepatocytes (n = 3). Fractional mean enrichment of central 
carbon metabolites and amino acids are estimated by measuring 13C enrichment of these metabolites in hepatocytes cultured with U[13C6]
glucose or U[13C6]glutamine. Fraction of metabolites not labeled by either U[13C6]glucose or U[13C6]glutamine are assumed to be 
derived from other carbon sources.
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Interestingly, there was no significant difference in 
the EGFR expression between normal and diseased 
liver specimens (Figs.  4 and 5A,B). However, the 
active form of EGFR, phospho-EGFR (Y1086), 
was highly expressed in hepatocytes derived 
from diseased livers of patients with decompen-
sated disease when compared with normal human 
hepatocytes (Supporting Fig.  S6). In addition, as 
continuous cycles of cell death and hepatocyte repli-
cation are hallmarks of cirrhosis,(1) we corroborated 
this observation in hepatocytes from patients with 
terminal liver failure, and demonstrated expression 
of replicative (phospho-H3[Ser10]) and cell death 
(active caspase 3) markers in end-stage hepato-
cytes using immunohistochemistry and western blot 
(Supporting Fig. S7A,B).
Because cMET can control AMPKα and AKT, 
and we found that cMET significantly down- 
regulated in hepatocytes from functionally decom-
pensated livers, we analyzed the activation 
processes for AMPKα and AKT. Total AMPKα, 
activated AMPKα(Thr172), and its ratio did not 
Fig. 4. Histological expression of molecular candidates that regulates HNF4α PTMs. (A) Representative images of serial 
immunohistochemistry analysis of EGFR, cMET, activated AMPK(Thr172), activated AKT(Ser473), and activated AKT(Thr308) in 
decompensated NASH human livers (n = 2), and alcohol-mediated Laennec’s cirrhotic livers (n = 2) compared with healthy human livers 
(n = 2). EGFR expression did not demonstrate any difference in its expression pattern among the groups, whereas cMET and activated 
AKT(Thr308) expression levels were decreased in all decompensated human livers.
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differ statistically between hepatocytes with decom-
pensated function and healthy human hepatocytes 
(Figs.  4 and 5A,B). However, total AKT, acti-
vated AKT(threonine 308 [Thr308]), and its ratio 
decreased significantly in liver specimens and iso-
lated hepatocytes from patients with decompensated 
hepatic function (Figs. 4 and 5A,B). Another AKT 
phosphorylation site (Ser473) was unchanged in 
liver specimens or isolated hepatocytes from healthy 
controls or decompensated specimens (Fig.  4 and 
Fig. 5A,B).
To further analyze the relationship among HNF4α, 
its nuclear localization, and PTM, we performed a 
Spearman’s rank correlation test. cMET expression 
showed a positive and statistically significant correla-
tion with total HNF4α (r = 0.76; P = 0.021; Fig. 5C) 
and nuclear HNF4α (r  =  0.71; P  =  0.037; Fig.  5C). 
Activated AKT(Thr308) also showed a positive and 
statistically significant correlation with total HNF4α 
(r  =  0.73; P  =  0.031; Fig.  5C) and nuclear HNF4α 
(r  =  0.82; P  =  0.011; Fig.  5C), whereas cytoplasmic 
HNF4α correlated negatively with cMET (r = −0.80; 
Fig. 5. Protein expression and Spearman’s rank correlation test of HNF4α PTMs. (A,B) Western blot analysis and quantification of 
EGFR (P = 0.904), cMET (P = 0.023), total AMPKα (P > 0.999), activated AMPKα(Thr172) (P = 0.547), total AKT (P = 0.047), 
activated AKT(Ser473) (P = 0.547), activated AKT(Thr308) (P = 0.024), activated AMPKα(Thr172)/AMPKα ratio (P = 5476), activated 
AKT(Ser473)/AKT ratio (P = 0.1667), and activated AKT(Thr308)/total AKT ratio (P = 0.0238) in decompensated NASH (n = 4) and 
alcohol-mediated Laennec’s cirrhotic freshly isolated hepatocytes (n = 2) and healthy control hepatocytes (n = 2). (C) Spearman’s rank 
correlation test of the western blot analysis and quantification showing significant correlation of nuclear HNF4α with cMET (r = 0.71; 
P = 0.037), total AKT (r = 0.71; P = 0.037), activated AKT(Thr308) (r = 0.82; P = 0.011), and activated AKT(Thr308)/total AKT ratio 
(r = 0.73; P = 0.031). Moreover, cytoplasmic HNF4α showed a significant correlation with cMET (r = −0.80; P = 0.014), total AKT 
(r = −0.73; P = 0.031), activated AKT(Thr308) (r = −0.77; P = 0.021, and activated AKT(Thr308)/total AKT ratio (r = −0.72; P = 0.037). 
Dot plots are shown as the mean ± SD; P < 0.05.
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P  =  0.014; Fig.  5C) and activated-AKT(Thr308) 
(r = −0.77; P = 0.021; Fig. 5C). In addition, the ratio 
of activated-AKT(Thr308)/total AKT correlated pos-
itively with cMET (r  =  0.80; P  =  0.014; Supporting 
Fig.  S6A) and total AKT (r  =  0.71; P  =  0.037; 
Supporting Fig. S6A). Thus, reduced cMET was asso-
ciated with reduced activation of the AKT pathway, 
reduced HNF4α in the nucleus, and more expression 
of HNF4α in the cytoplasm.
nuCleaR loCaliZation oF  
HnF4α is aFFeCteD By tHe  
cmet/aKt aXis anD CoRRelates 
WitH eXtent oF liVeR 
DysFunCtion
As seen in Fig.  6A, pathway analysis revealed a 
significant causal relationship between cMET expres-
sion and nuclear HNF4α expression (0.56; P = 0.004) 
Fig. 6. Relationship of PTMs and HNF4α cellular localization. (A) Schematic diagramming of the path analysis performed with protein 
expression revealed a significant direct relationship between nuclear HNF4α and cMET (0.56; P = 0.004), activated AKT(Thr308)/total 
AKT ratio (0.05; P = 0.006), and total HNF4α levels (0.60; P = 0.042). Path analysis also shows a negative significant relationship between 
cMET and total HNF4α (−0.37; P = 0.024). (B) Linear regression graph analysis shows the significant relationship of nuclear HNF4α 
expression and the degree of liver dysfunction (Child-Pugh score) (R2 = 0.80, P = 0.007). (C,D) PCA and dot plots of the protein profile 
showing correlations with hepatocyte functional characteristics. cMET, activated AKT(Thr308)/total AKT ratio, and total and nuclear 
HNF4α expression positively explain the characteristics of healthy human hepatocytes (n  =  2), whereas cytoplasmic HNF4α, active 
caspase 3, activated AKT(Ser473)/total AKT ratio, and p-AMPK(Ser172)/AMPK explain the characteristics of decompensated human 
hepatocytes from NASH (n = 4) and alcohol-mediated Laennec’s cirrhotic livers (n = 2). (D) Dot plots are shown as the mean ± SD; 
P < 0.05.
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and a direct relationship between levels of nuclear 
HNF4α and the activated AKT(Thr308)/total AKT 
ratio (0.05; P  =  0.006). Modeling also demonstrated 
that total HNF4α expression levels contribute to 
nuclear localization (0.60; P  =  0.042). However, 
cMET expression was negatively associated with total 
HNF4α expression (−0.37; P = 0.024) (Fig. 6A), indi-
cating that cMET expression does not directly affect 
total HNF4α expression but only its nuclear localiza-
tion. To assess whether the levels of nuclear expression 
correlate with extent of liver dysfunction (Child-Pugh 
score), we performed a linear regression analysis and 
found that nuclear HNF4α expression levels have a 
significant inverse relationship with the Child-Pugh 
score (R2 = 0.80; P = 0.007) (Fig. 6B). Together, these 
pathway and linear regression statistical analyses of 
protein expression suggest that HNF4α localization is 
associated with hepatic disease progression and that 
cMET expression and AKT phosphorylation may 
play a central role in maintaining hepatocyte HNF4α 
nuclear localization and function.
Next, PCA was performed to validate our previous 
findings on HNF4α posttranslation modifier-related 
molecules, and to delineate whether a pattern of mole-
cules exist that correlates with hepatic function in end-
stage hepatocytes (Child-Pugh score) (Fig. 6C, D). As 
shown in Fig. 6C, principal component 1 (PC1; 69.9%) 
and PC2 (30.1%) discriminate 100% of the variability 
in level of hepatic function (Child-Pugh score) in the 
isolated hepatocytes studied. The vectors that charac-
terized normal human hepatocytes were cMET and 
activated AKT(Thr308)/total AKT ratio, total HNF4α, 
and nuclear HNF4α, whereas the negative character-
istics, which characterized failing human hepatocytes, 
were cytoplasmic HNF4α and active caspase 3 expres-
sion (Fig.  6C,D). Together, this statistical analysis 
corroborates our molecular profiling of human hepato-
cytes with terminal liver failure and establishes a causal 
connection among the expression of cMET, activated 
AKT(Thr308), and total and nuclear HNF4α.
Retention oF HnF4α in 
tHe nuCleus is ReDuCeD in 
patients WitH enD-stage 
liVeR FailuRe tHRougH 
DeCReaseD aCetylation
One of the targets of AKT is activation of the cyclic 
adenosine monophosphate response element-binding 
protein (CREB).(44) It is well known that the CREB-
binding protein has an intrinsic acetylation activity 
on nucleosomal histones, which increase the access of 
transcription factors to nucleosomal DNA and there-
fore activate transcription and retention of transcrip-
tion factors in nuclei. Thus, this axis could be related to 
HNF4α nuclear retention.(19) As genome-wide tran-
scriptome analysis and our in silico analysis suggested 
that the cMET/AKT kinase axis pathway could con-
trol HNF4α localization and stability through the acti-
vation of the CREB-binding protein,(39) we measured 
nuclear expression of acetylated HNF4α (Fig. 7A-C) 
and found that HNF4α acetylation in the nucleus and 
nuclear acetylated HNF4α/total HNF4α ratio were 
significantly reduced in hepatocytes from patients with 
terminal liver failure when compared with healthy 
controls (P = 0.024 and P = 0.0001; Fig. 7B). In addi-
tion, to confirm that acetylation of HNF4α relates to 
the extent of liver dysfunction (Child-Pugh score), we 
performed a linear regression analysis and found that 
a decrease in acetylated HNF4α correlates directly 
and significantly with liver dysfunction (R2  =  0.71; 
P = 0.004; Fig. 7C). As a proof of principle, we con-
ducted preliminary experiments in freshly isolated 
normal human hepatocytes by inhibiting AKT signal-
ing to corroborate the role of activated-AKT(Thr308) 
in HNF4α nuclear localization. Freshly isolated nor-
mal human hepatocytes were treated with MK-2206, 
a potent allosteric pan-AKT inhibitor.(45) After 
24 hours of AKT-inhibitory treatment, 80% of acti-
vated AKT(Thr308), 25% of nuclear HNF4α, and 
14% of acetylated nuclear HNF4α expression were 
reduced when compared with the nontreated controls.
Discussion
HNF4α is the master regulator of liver 
function.(13-15,17-21,23,25) Alterations in HNF4α 
expression have been described in hepatocellular 
carcinoma (HCC), hepatitis B, hepatitis C, alcohol- 
mediated hepatitis and cirrhosis, as well as 
NASH.(13-15,17-21,23,25,46) In an animal model of termi-
nal chronic liver failure, HNF4α expression was found 
to be severely reduced, and restoration of HNF4 
expression using gene therapy resulted in normal-
ization of hepatocyte function.(12) To assess whether 
this observation applies to humans, we studied liver- 
enriched transcription factor expression in the livers 
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of a large cohort of patients with decompensated liver 
function.(5) We found that HNF4α mRNA levels 
were down-regulated and correlated with the extent of 
liver dysfunction based on Child-Pugh classification. 
Interestingly, in those studies, nuclear localization of 
HNF4α was not uniform.(5)
In the present study, we isolated human hepato-
cytes from the explanted livers of patients with cirrho-
sis and end-stage (Child-Pugh B and C) liver failure 
caused by NASH and alcohol-mediated Laennec’s 
cirrhosis. In these isolated hepatocytes, there was an 
increase in HNF4α located in the cytoplasm and a 
decrease in HNF4α in the nucleus compared with 
that seen in control healthy hepatocytes. In addition, 
localization of HNF4α to the cytoplasm or nucleus 
in human-failing cirrhotic hepatocytes correlated with 
the degree of hepatocyte dysfunction. These findings 
suggest that pathways regulating HNF4α nuclear 
transport or retention could potentially be targets for 
the treatment of terminal liver failure.
The role of metabolic alterations is becoming evi-
dent in the development of terminal liver failure and 
HCC.(37,47) We previously found that rat hepatocytes 
in early stages of cirrhosis switch to glycolysis to meet 
Fig. 7. Acetylation of nuclear HNF4α is altered in human decompensated hepatocytes from NASH and alcohol-mediated Laennec’s 
cirrhotic explanted livers. (A,B) Western blots and quantification of the acetylated form of HNF4α(Lys106) in the nuclear fraction of 
human hepatocytes from decompensated NASH (n = 4) and alcohol-mediated Laennec’s cirrhotic (n = 4) hepatocytes, normalized to 
nuclear marker HDAC1 (P = 0.024) or total HNF4α expression (P = 0001). (C) Linear regression graph analysis shows a significant 
correlation of reduced acetylated form of HNF4α(Lys106) and liver dysfunction (R2 = 0.71, P = 0.004). (D) Diagram of the proposed 
model of regulation of HNF4α location and its association with terminal liver failure. cMET and activated AKT(Thr308) are down-
regulated in hepatocytes from patients with NASH and alcohol-mediated Laennec’s cirrhosis-related terminal liver failure, which decreases 
HNF4α acetylation and retention in the nucleus. Dot plot (B) is shown as the mean ± SD; P < 0.05.
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their energy requirements as a compensation for the 
decreased oxidative phosphorylation. We found similar 
metabolic profiling in human hepatocytes from livers 
with end-stage liver failure. Human normal hepato-
cytes were able to use both pyruvate carboxylase and 
pyruvate dehydrogenase to fuel the TCA cycle, whereas 
human cirrhotic decompensated hepatocytes rely pri-
marily on pyruvate dehydrogenase to fuel TCA from 
glucose. Moreover, we found that human cirrhotic 
decompensated hepatocytes showed a dysfunctional 
oxidative TCA, a phenomenon previously observed 
only in rat cirrhotic decompensated hepatocytes.(37) It 
is important to note that HCC normally rises from 
liver cirrhosis and relies primarily on a glycolytic 
phenotype.(47) Thus, it would be important to deter-
mine in future studies the metabolic mechanistic links 
among liver cirrhosis, terminal liver failure, and HCC.
AMPK and AKT kinases were identified by in silico 
and RNA-seq analyses as molecular pathways that 
might regulate HNF4α localization.(16,18,19) AMPK 
plays a central role in maintaining energy homeostasis, 
promoting adenosine triphosphate (ATP) production, 
and reducing ATP consumption,(48) whereas AKT 
activation promotes cell proliferation, survival, and 
growth.(49,50) AKT activation is mediated by phos-
phorylation at threonine 308 and/or serine 473.(46,47) 
In our studies, we found a significant correlation 
between activated-AKT(Thr308) and HNF4α local-
ization, as activated-AKT(Thr308) levels were sig-
nificantly decreased in end-stage human hepatocytes. 
These findings indicate that AKT phosphorylation at 
Thr308 may play an important role in hepatocyte fail-
ure in terminal stages of liver disease.
We then analyzed two central receptors that 
are upstream regulators of AKT and AMPK and 
related to liver function and regeneration: cMET and 
EGFR.(26,41-43) We have reported in mice that com-
bined disruption of cMET and EGFR alters liver 
homeostasis and leads to terminal liver failure.(43) In 
human failing cirrhotic hepatocytes, there was reduced 
expression of cMET, and decreased expression cor-
related directly with HNF4α localization. In contrast, 
there was no difference in total EGFR expression in 
either human failing cirrhotic hepatocytes or control 
human hepatocytes. Thus, in human liver, cMET 
might play an important role in regulating AKT path-
way activation and HNF4α localization and function.
Moreover, by using different statistical analyses 
(Spearman’s rank correlation test, pathway analysis, 
linear regression analysis, and PCA), we were able to 
establish the association between the PTMs analyzed 
in human failing cirrhotic and healthy hepatocytes. 
Not surprisingly, these statistical analyses revealed 
that cMET and activated-AKT(Thr308) were 
directly related to the expression levels of nuclear 
HNF4α. An intriguing finding is the negative asso-
ciation found between cMET protein expression and 
total HNF4α, indicating that cMET expression does 
not directly affect total HNF4α expression but only 
its nuclear localization. Based on the low expression 
levels of activated AKT(Thr308) in human failing 
cirrhotic hepatocytes and the direct effect of AKT 
on CREB-binding protein, a molecule that has an 
intrinsic acetylation activity that increases tran-
scription factor binding to nucleosomal DNA, we 
hypothesized that the acetylation of HNF4α might 
be affected in the cirrhotic failing hepatocytes. 
Indeed, nuclear HNF4α acetylation was strikingly 
reduced in human hepatocytes from cirrhotic liv-
ers, and its level was associated with the degree of 
hepatic dysfunction. Moreover, although preliminary 
experiments presented here using healthy human 
hepatocytes and allosteric pan-AKT inhibitor cor-
roborated the relationship of AKT and the nuclear 
expression of HNF4α. These observations suggest 
that AKT phosphorylation at Thr308 mediates the 
HNF4α nuclear retention through acetylation, pos-
sibly by controlling the CREB-binding protein(19) 
(Fig.  6D). Future experiments should explore the 
forced expression of these additional targets in con-
junction with HNF4α in human hepatocytes in end-
stage cirrhotic livers, to determine what role they 
may play in causing terminal hepatocyte failure, and 
potentially treating it.
In summary, these results suggest that localization 
of HNF4α in the cytoplasm results from alterations 
of the molecular pathways, which maintain HNF4α 
in the nucleus during advanced stages of liver dis-
ease. cMET and activated AKT(Thr308) are down- 
regulated and affect acetylation and nuclear retention 
of HNF4α (Fig. 6D). These findings may have ther-
apeutic implications for the restoration of hepatocyte 
function in chronic liver diseases.
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